New 52 Week High Today

Iteos Therapeutics Inc ITOS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/03/21 EST
43.49UNCH (UNCH)
Volume
478
Close
43.49quote price arrow down-0.71 (-1.61%)
Volume
186,626
52 week range
17.50 - 47.61

...

Loading . . .

KEY STATS

  • Open44.11
  • Day High47.61
  • Day Low41.72
  • Prev Close43.49
  • 52 Week High47.61
  • 52 Week High Date03/03/21
  • 52 Week Low17.50
  • 52 Week Low Date07/27/20
  • Market Cap1.524B
  • Shares Out35.04M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.02
  • P/E (TTM)-42.55
  • Fwd P/E (NTM)-22.71
  • EBITDA (MRQ)-29.588M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Iteos Therapeutics Inc News

There is no recent news for this security.

Latest ITOS News From Our Partners

QUOTE FINDER

Profile

MORE
iTeos Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovery and development of a differentiated immuno-oncology therapeutics for patients. The Company’s pipeline includes two clinical-stage programs EOS-448 and EOS-850. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company’s lead antibody product candidate, EOS-448...
David Hallal
Chairman
Michel Detheux
Chief Executive Officer
Matthew Callister M.D.
Chief Operating Officer
Matthew Gall
Chief Financial Officer
Address
139 Main Street
Cambridge, MA
02142
United States